These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38326205)

  • 1. Sarcopenia Affects Liver Regeneration and Long-Term Survival Rate After Living-Donor Liver Transplantation in Patients With Hepatocellular Carcinoma.
    Wu MY; Yeh CH; Liao CC; Chen CL; Wang CC; Lin CC; Chang WC; Cheng YF; Ou HY
    Transplant Proc; 2024 Apr; 56(3):573-580. PubMed ID: 38326205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia adversely impacts postoperative complications in living-donor liver transplantation recipients.
    Wu MY; Lim WX; Cheng YF; Chang CD; Hsu HW; Lin CC; Chen CL; Chang WC; Yu CY; Tsang LL; Chuang YH; Ou HY
    Sci Rep; 2021 Sep; 11(1):19247. PubMed ID: 34584142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia defined by psoas muscle index independently predicts long-term survival after living donor liver transplantation in male recipients.
    Tan Y; Duan T; Li B; Zhang B; Zhu Y; Yan K; Song J; Lv T; Yang J; Jiang L; Yang J; Wen T; Yan L
    Quant Imaging Med Surg; 2022 Jan; 12(1):215-228. PubMed ID: 34993073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative loss of psoas muscle is associated with patient survival in living donor liver transplantation.
    Chae MS; Moon KU; Jung JY; Choi HJ; Chung HS; Park CS; Lee J; Choi JH; Hong SH
    Liver Transpl; 2018 May; 24(5):623-633. PubMed ID: 29365358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses.
    Wong TCL; Ng KKC; Fung JYY; Chan AAC; Cheung TT; Chok KSH; Dai JWC; Lo CM
    Ann Surg Oncol; 2019 May; 26(5):1454-1462. PubMed ID: 30737669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort.
    Kulik LM; Fisher RA; Rodrigo DR; Brown RS; Freise CE; Shaked A; Everhart JE; Everson GT; Hong JC; Hayashi PH; Berg CL; Lok AS;
    Am J Transplant; 2012 Nov; 12(11):2997-3007. PubMed ID: 22994906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
    Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
    Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.
    Xiao GQ; Song JL; Shen S; Yang JY; Yan LN
    World J Gastroenterol; 2014 Aug; 20(31):10953-9. PubMed ID: 25152599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    Yoon YI; Song GW; Lee SG; Hwang S; Kim KH; Kim SH; Kang WH; Cho HD; Jwa EK; Kwon JH; Tak EY; Kirchner VA
    J Hepatol; 2018 Jun; 68(6):1153-1162. PubMed ID: 29452208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis.
    Liang W; Wu L; Ling X; Schroder PM; Ju W; Wang D; Shang Y; Kong Y; Guo Z; He X
    Liver Transpl; 2012 Oct; 18(10):1226-36. PubMed ID: 22685095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of hepatocellular carcinoma treated by liver transplantation: comparison of living donor and deceased donor transplantation.
    Li C; Wen TF; Yan LN; Li B; Yang JY; Wang WT; Xu MQ; Wei YG
    Hepatobiliary Pancreat Dis Int; 2010 Aug; 9(4):366-9. PubMed ID: 20688599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Tumor Necrosis Factor-α Is Inversely Associated With the Psoas Muscle Index in Both Male and Female Patients Scheduled for Living Donor Liver Transplantation.
    Shim JW; Yang S; Jung JY; Choi HJ; Chung HS; Hong SH; Park CS; Choi JH; Chae MS
    Transplant Proc; 2019; 51(6):1874-1879. PubMed ID: 31262437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant.
    Lai Q; Sapisochin G; Gorgen A; Vitale A; Halazun KJ; Iesari S; Schaefer B; Bhangui P; Mennini G; Wong TCL; Uemoto S; Lin CC; Mittler J; Ikegami T; Yang Z; Frigo AC; Zheng SS; Soejima Y; Hoppe-Lotichius M; Chen CL; Kaido T; Lo CM; Rossi M; Soin AS; Finkenstedt A; Emond JC; Cillo U; Lerut JP
    JAMA Surg; 2021 Sep; 156(9):e213112. PubMed ID: 34259797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence.
    Sandhu L; Sandroussi C; Guba M; Selzner M; Ghanekar A; Cattral MS; McGilvray ID; Levy G; Greig PD; Renner EL; Grant DR
    Liver Transpl; 2012 Mar; 18(3):315-22. PubMed ID: 22140013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter.
    Dai WC; Chan SC; Chok KS; Cheung TT; Sharr WW; Chan AC; Tsang SH; Fung JY; Poon RT; Fan ST; Lo CM
    HPB (Oxford); 2014 Aug; 16(8):749-57. PubMed ID: 24467735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.
    Wan P; Zhang JJ; Li QG; Xu N; Zhang M; Chen XS; Han LZ; Xia Q
    World J Gastroenterol; 2014 Apr; 20(15):4393-400. PubMed ID: 24764678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma.
    Ninomiya M; Shirabe K; Facciuto ME; Schwartz ME; Florman SS; Yoshizumi T; Harimoto N; Ikegami T; Uchiyama H; Maehara Y
    J Am Coll Surg; 2015 Mar; 220(3):297-304.e3. PubMed ID: 25617912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.